# Nuclide record idea-rlt-plus-parp-inhibitor (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-rlt-plus-parp-inhibitor/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-rlt-plus-parp-inhibitor" ;
  schema:name "Adding a PARP inhibitor to PSMA radioligand therapy"@en ;
  schema:description "A drug that blocks a cell's DNA-repair enzyme (PARP) is being added to PSMA-targeted radioactive treatment, on the theory that if a cell can't repair the small cuts radiation makes to its DNA, those cuts become fatal breaks that kill the cancer cell."@en ;
  schema:url <https://nuclide.cc/ideas/idea-rlt-plus-parp-inhibitor/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5005>, <https://clinicaltrials.gov/study/NCT03874884>, <https://nuclide-hema.healthbooktimes.org/article/154290-recent-advances-in-radioligand-therapy>, <https://clinicaltrials.gov/study/NCT06909825> ;
  nuclide:tag "combination therapy", "PARP", "prostate" ;
  nuclide:related <https://nuclide.cc/technologies/radionuclide-parp-combination/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/olaparib/>, <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/people/sandhu-shahneen/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> .